Generic Name and Formulations:
Ticarcillin (as disodium) 3g, clavulanate (as potassium) 0.1g; IV inj; sodium content 4.75mEq/g of ticarcillin; potassium content 0.15mEq/g of Timentin.
Indications for TIMENTIN:
Susceptible bacterial septicemia (adults only), lower respiratory, bone and joint, skin and skin structure, urinary tract, gynecologic and intraabdominal infections.
By IV infusion over 30 minutes. >60kg: Systemic and UTI: 3.1g every 4–6 hours. Gynecologic: moderate: 200mg/kg/day of ticarcillin in divided doses every 6 hours; severe: 300mg/kg/day in divided doses every 4 hours. <60kg: 200–300mg/kg/day in divided doses every 4–6 hours. Renal impairment: reduce dose; see literature.
<3months: not recommended. Give by IV infusion over 30 minutes. ≥3months: (<60kg): mild-to-moderate infections: 200mg/kg per day of ticarcillin in equal divided doses every 6 hrs: severe infections: 300mg/kg per day of ticarcillin in equal divided doses every 4 hours. ≥3months (≥60kg): mild-to-moderate infections: 3.1g every 6 hrs; severe infections: 3.1g every 4 hours. Renal impairment: reduce dose; see literature.
Cephalosporin, imipenem or other allergy. Not for use in children for septicemia or H. influenzae type b infections. Heart disease. Sodium restricted diets. Monitor serum electrolytes (esp. potassium) and renal, hepatic, hematopoietic function during prolonged therapy. Discontinue if bleeding problems occur and treat. Pregnancy (Cat.B). Nursing mothers.
Antipseudomonal penicillin + β-lactamase inhibitor.
Probenecid increases ticarcillin levels. May cause false (+) Coomb's test.
Inj site reactions, rash, pruritus, drug fever, GI upset, blood dyscrasias, hemorrhage, hypokalemia, superinfection, anaphylaxis, CNS stimulation, elevated liver enzymes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC